Vemurafenib and cutaneous adverse events - report of five cases

Detalhes bibliográficos
Autor(a) principal: Silva,Giselle de Barros
Data de Publicação: 2015
Outros Autores: Mendes,Adriana Pessoa, Macedo,Mariana Petaccia de, Pinto,Clóvis Antônio Lopes, Gibbons,Ivana Lameiras, Duprat Neto,João Pedreira
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Anais brasileiros de dermatologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962015000700242
Resumo: Abstract Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatment. We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its cutaneous adverse events. Dermatologists and oncologists need to be aware of possible skin changes caused by this medication, which is increasingly employed in melanoma treatment. Monitoring of patients during therapy is important for early treatment of adverse cutaneous cutaneous adverse events, improvement in quality of life and adherence to treatment.
id SBD-1_dde66c8d31150698f11f8b108c5b2830
oai_identifier_str oai:scielo:S0365-05962015000700242
network_acronym_str SBD-1
network_name_str Anais brasileiros de dermatologia (Online)
repository_id_str
spelling Vemurafenib and cutaneous adverse events - report of five casesDrug eruptionsDrug therapyMelanomaAbstract Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatment. We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its cutaneous adverse events. Dermatologists and oncologists need to be aware of possible skin changes caused by this medication, which is increasingly employed in melanoma treatment. Monitoring of patients during therapy is important for early treatment of adverse cutaneous cutaneous adverse events, improvement in quality of life and adherence to treatment.Sociedade Brasileira de Dermatologia2015-06-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962015000700242Anais Brasileiros de Dermatologia v.90 n.3 suppl.1 2015reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1590/abd1806-4841.20153841info:eu-repo/semantics/openAccessSilva,Giselle de BarrosMendes,Adriana PessoaMacedo,Mariana Petaccia dePinto,Clóvis Antônio LopesGibbons,Ivana LameirasDuprat Neto,João Pedreiraeng2015-11-19T00:00:00Zoai:scielo:S0365-05962015000700242Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2015-11-19T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false
dc.title.none.fl_str_mv Vemurafenib and cutaneous adverse events - report of five cases
title Vemurafenib and cutaneous adverse events - report of five cases
spellingShingle Vemurafenib and cutaneous adverse events - report of five cases
Silva,Giselle de Barros
Drug eruptions
Drug therapy
Melanoma
title_short Vemurafenib and cutaneous adverse events - report of five cases
title_full Vemurafenib and cutaneous adverse events - report of five cases
title_fullStr Vemurafenib and cutaneous adverse events - report of five cases
title_full_unstemmed Vemurafenib and cutaneous adverse events - report of five cases
title_sort Vemurafenib and cutaneous adverse events - report of five cases
author Silva,Giselle de Barros
author_facet Silva,Giselle de Barros
Mendes,Adriana Pessoa
Macedo,Mariana Petaccia de
Pinto,Clóvis Antônio Lopes
Gibbons,Ivana Lameiras
Duprat Neto,João Pedreira
author_role author
author2 Mendes,Adriana Pessoa
Macedo,Mariana Petaccia de
Pinto,Clóvis Antônio Lopes
Gibbons,Ivana Lameiras
Duprat Neto,João Pedreira
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Silva,Giselle de Barros
Mendes,Adriana Pessoa
Macedo,Mariana Petaccia de
Pinto,Clóvis Antônio Lopes
Gibbons,Ivana Lameiras
Duprat Neto,João Pedreira
dc.subject.por.fl_str_mv Drug eruptions
Drug therapy
Melanoma
topic Drug eruptions
Drug therapy
Melanoma
description Abstract Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatment. We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its cutaneous adverse events. Dermatologists and oncologists need to be aware of possible skin changes caused by this medication, which is increasingly employed in melanoma treatment. Monitoring of patients during therapy is important for early treatment of adverse cutaneous cutaneous adverse events, improvement in quality of life and adherence to treatment.
publishDate 2015
dc.date.none.fl_str_mv 2015-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962015000700242
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962015000700242
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/abd1806-4841.20153841
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
dc.source.none.fl_str_mv Anais Brasileiros de Dermatologia v.90 n.3 suppl.1 2015
reponame:Anais brasileiros de dermatologia (Online)
instname:Sociedade Brasileira de Dermatologia (SBD)
instacron:SBD
instname_str Sociedade Brasileira de Dermatologia (SBD)
instacron_str SBD
institution SBD
reponame_str Anais brasileiros de dermatologia (Online)
collection Anais brasileiros de dermatologia (Online)
repository.name.fl_str_mv Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)
repository.mail.fl_str_mv abd@sbd.org.br||revista@sbd.org.br
_version_ 1752126420959625216

Registros relacionados